BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Debray D, Narkewicz MR, Bodewes FAJA, Colombo C, Housset C, de Jonge HR, Jonker JW, Kelly DA, Ling SC, Poynard T, Sogni P, Trauner M, Witters P, Baumann U, Wilschanski M, Verkade HJ. Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives. J Pediatr Gastroenterol Nutr. 2017;65:443-448. [PMID: 28753176 DOI: 10.1097/mpg.0000000000001676] [Cited by in Crossref: 49] [Cited by in F6Publishing: 18] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Yokoda RT, Rodriguez EA. Review: Pathogenesis of cholestatic liver diseases. World J Hepatol 2020; 12(8): 423-435 [PMID: 32952871 DOI: 10.4254/wjh.v12.i8.423] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
2 Fiorotto R, Amenduni M, Mariotti V, Cadamuro M, Fabris L, Spirli C, Strazzabosco M. Animal models for cystic fibrosis liver disease (CFLD). Biochim Biophys Acta Mol Basis Dis 2019;1865:965-9. [PMID: 30071276 DOI: 10.1016/j.bbadis.2018.07.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Galante GJ. Defining and Treating Cystic Fibrosis Liver Disease: Some Things Old and Some Things New. J Cyst Fibros 2022;21:199-201. [PMID: 35337600 DOI: 10.1016/j.jcf.2022.03.004] [Reference Citation Analysis]
4 Loukou I, Moustaki M, Sardeli O, Plyta M, Katsagoni CN, Douros K. Association of vitamin A status with lung function in children and adolescents with cystic fibrosis. Pediatr Investig 2021;5:125-9. [PMID: 34179709 DOI: 10.1002/ped4.12270] [Reference Citation Analysis]
5 Więcek S, Woś H, Pogorzelski A, Kordys-Darmolinska B, Mazurek H, Grzybowska-Chlebowczyk U. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis. Mediators Inflamm 2020;2020:5696185. [PMID: 32308556 DOI: 10.1155/2020/5696185] [Reference Citation Analysis]
6 Baldissera M, Lewindon PJ, Ramm LE, Hartel GF, Mattiello R, Ramm GA. Advanced but not mild liver disease is a predictor of decreased survival in children with cystic fibrosis, with far greater impact in females: A 27-year real-life cohort study. J Cyst Fibros 2021:S1569-1993(21)02156-1. [PMID: 34949555 DOI: 10.1016/j.jcf.2021.11.015] [Reference Citation Analysis]
7 Briaud P, Bastien S, Camus L, Boyadjian M, Reix P, Mainguy C, Vandenesch F, Doléans-Jordheim A, Moreau K. Impact of Coexistence Phenotype Between Staphylococcus aureus and Pseudomonas aeruginosa Isolates on Clinical Outcomes Among Cystic Fibrosis Patients. Front Cell Infect Microbiol 2020;10:266. [PMID: 32582568 DOI: 10.3389/fcimb.2020.00266] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
8 Glutig K, Krüger PC, Oberreuther T, Nickel MD, Teichgräber U, Lorenz M, Mentzel HJ, Krämer M. Preliminary results of abdominal simultaneous multi-slice accelerated diffusion-weighted imaging with motion-correction in patients with cystic fibrosis and impaired compliance. Abdom Radiol (NY) 2022. [PMID: 35596778 DOI: 10.1007/s00261-022-03549-7] [Reference Citation Analysis]
9 Jaspers E, Van Dijck I, Hoffman I, Knops N, Stéphenne X, Witters P, Proesmans M. Cystic fibrosis and alpha-1 antitrypsin deficiency: case report and review of literature. BMC Pediatr 2022;22:247. [PMID: 35505316 DOI: 10.1186/s12887-022-03290-6] [Reference Citation Analysis]
10 Calvopina DA, Lewindon PJ, Ramm LE, Noble C, Hartel GF, Leung DH, Ramm GA. Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric Cystic Fibrosis. J Cyst Fibros 2021:S1569-1993(21)02171-8. [PMID: 34953741 DOI: 10.1016/j.jcf.2021.10.014] [Reference Citation Analysis]
11 McBennett K, MacAskill CJ, Keshock E, Mahani MG, Mata J, Towbin AJ, Sankararaman S, Drumm ML, Yu X, Ren CL, Nasr SZ, Kutney K, Flask CA. Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies. J Cyst Fibros 2021:S1569-1993(21)02143-3. [PMID: 34879996 DOI: 10.1016/j.jcf.2021.11.006] [Reference Citation Analysis]
12 Martonosi ÁR, Soós A, Rumbus Z, Hegyi P, Izsák V, Pázmány P, Imrei M, Váncsa S, Szakács Z, Párniczky A. Non-invasive Diagnostic Tests in Cystic Fibrosis-Related Liver Disease: A Diagnostic Test Accuracy Network Meta-Analysis. Front Med (Lausanne) 2021;8:598382. [PMID: 34386504 DOI: 10.3389/fmed.2021.598382] [Reference Citation Analysis]
13 Ye W, Leung DH, Molleston JP, Ling SC, Murray KF, Nicholas JL, Huang S, Karmazyn BW, Harned RK, Masand P, Alazraki AL, Navarro OM, Otto RK, Palermo JJ, Towbin AJ, Alonso EM, Karnsakul WW, Jane Schwarzenberg S, Seidel GF, Siegel M, Magee JC, Narkewicz MR, Jay Freeman A. Association Between Transient Elastography and Controlled Attenuated Parameter and Liver Ultrasound in Children With Cystic Fibrosis. Hepatol Commun 2021;5:1362-72. [PMID: 34430781 DOI: 10.1002/hep4.1719] [Reference Citation Analysis]
14 Ramsey ML, Wellner MR, Porter K, Kirkby SE, Li SS, Lara LF, Kelly SG, Hanje AJ, Sobotka LA. Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis. World J Hepatol 2022; 14(2): 411-419 [DOI: 10.4254/wjh.v14.i2.411] [Reference Citation Analysis]
15 Norsa L, Zazzeron L, Cuomo M, Claut L, Bulfamante AMC, Biffi A, Colombo C. Night Blindness in Cystic Fibrosis: The Key Role of Vitamin A in the Digestive System. Nutrients 2019;11:E1876. [PMID: 31412557 DOI: 10.3390/nu11081876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2018;34:146-51. [PMID: 29438119 DOI: 10.1097/MOG.0000000000000432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
17 Mandato C, Di Nuzzi A, Vajro P. Nutrition and Liver Disease. Nutrients 2017;10:E9. [PMID: 29295475 DOI: 10.3390/nu10010009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
18 Wiecek S, Fabrowicz P, Wos H, Kordys-darmolinska B, Cebula M, Gruszczynska K, Grzybowska-chlebowczyk U, Liu Z. Assessment of Liver Fibrosis with the Use of Elastography in Paediatric Patients with Diagnosed Cystic Fibrosis. Disease Markers 2022;2022:1-8. [DOI: 10.1155/2022/4798136] [Reference Citation Analysis]
19 Toledano MB, Mukherjee SK, Howell J, Westaby D, Khan SA, Bilton D, Simmonds NJ. The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study. PLoS One 2019;14:e0212779. [PMID: 30947265 DOI: 10.1371/journal.pone.0212779] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
20 Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
21 Viotti Perisse I, Fan Z, Van Wettere A, Liu Y, Leir SH, Keim J, Regouski M, Wilson MD, Cholewa KM, Mansbach SN, Kelley TJ, Wang Z, Harris A, White KL, Polejaeva IA. Sheep models of F508del and G542X cystic fibrosis mutations show cellular responses to human therapeutics. FASEB Bioadv 2021;3:841-54. [PMID: 34632318 DOI: 10.1096/fba.2021-00043] [Reference Citation Analysis]
22 Enaud R, Frison E, Missonnier S, Fischer A, de Ledinghen V, Perez P, Bui S, Fayon M, Chateil JF, Lamireau T. Cystic fibrosis and noninvasive liver fibrosis assessment methods in children. Pediatr Res 2021. [PMID: 33731812 DOI: 10.1038/s41390-021-01427-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]
24 Fabris L, Fiorotto R, Spirli C, Cadamuro M, Mariotti V, Perugorria MJ, Banales JM, Strazzabosco M. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nat Rev Gastroenterol Hepatol 2019;16:497-511. [PMID: 31165788 DOI: 10.1038/s41575-019-0156-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
25 Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cell Mol Gastroenterol Hepatol 2019;8:197-207. [PMID: 31075352 DOI: 10.1016/j.jcmgh.2019.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
26 Debray D, El Mourabit H, Merabtene F, Brot L, Ulveling D, Chrétien Y, Rainteau D, Moszer I, Wendum D, Sokol H, Housset C. Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. Hepatol Commun 2018;2:1533-49. [PMID: 30556040 DOI: 10.1002/hep4.1266] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
27 Tchoukaev A, Taytard J, Rousselet N, Rebeyrol C, Debray D, Blouquit-Laye S, Moisan MP, Foury A, Guillot L, Corvol H, Tabary O, Le Rouzic P. Opposite Expression of Hepatic and Pulmonary Corticosteroid-Binding Globulin in Cystic Fibrosis Patients. Front Pharmacol 2018;9:545. [PMID: 29922157 DOI: 10.3389/fphar.2018.00545] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Loukou I, Petrocheilou A, Moustaki M, Katsagoni CN, Douros K. Cystic fibrosis drug approved for patients aged 6-11 years worked well in clinical practice. Acta Paediatr 2021;110:228-9. [PMID: 32762058 DOI: 10.1111/apa.15519] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Boëlle PY, Debray D, Guillot L, Clement A, Corvol H; French CF Modifier Gene Study Investigators. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology 2019;69:1648-56. [PMID: 30058245 DOI: 10.1002/hep.30148] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]